Skip to main content
    H

    Halozyme Therapeutics Inc (HALO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $95.97
    -0.53 (-0.55%)

    Market Cap: $11.00B

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Halozyme Therapeutics Inc (HALO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Halozyme Therapeutics (HALO) has a market cap of $11.00B and an enterprise value of $13.22B. Revenue grew 45.03% over the last 12 months from the 12 months before. Its return on invested capital of 15.84% compares with a 1.77% median across 6 similar companies.

    Total Valuation

    Enterprise value is 20.18% above the market cap, as debt exceeds cash.

    Market Cap$11.00B
    Enterprise Value$13.22B
    Latest price (Nov 17, 2026)$95.97

    Key Dates

    The next earnings report is expected on Jan 26, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateJan 26, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 2.96% in the quarter ended Sep 30, 2026 and shrank 5.28% a year over 2 years.

    Shares Outstanding113.80M
    Shares Change (YoY)-2.92%
    Shares Change (QoQ)-2.96%
    Share Count Growth (2Y CAGR)-5.28%

    Valuation Ratios

    The price to sales ratio is 6.1x. Its year-end P/E ranged from 11.3x to 53.3x from 2017 to 2025.

    P/E Ratio17.7x
    Forward P/E10.6x
    P/S Ratio6.1x
    Forward P/S5.8x
    P/FCF Ratio12.3x
    P/OCF Ratio12.2x
    PEG Ratio3.1

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 16.0x EBITDA and 14.8x free cash flow.

    EV / Earnings27.2x
    EV / Sales7.3x
    EV / EBITDA16.0x
    EV / EBIT19.4x
    EV / FCF14.8x

    Price Statistics

    The stock is up 37.04% over 52 weeks and trades 15.85% below its 50-day average.

    Beta (1Y)0.62
    52-Week Change+37.04%
    1-Month Change-21.66%
    3-Month Change-10.83%
    6-Month Change+39.63%
    5-Year Change+243.87%
    10-Year Change+1416.92%
    Total Return (1Y)+37.04%
    Total Return (3Y CAGR)+33.94%
    Total Return (5Y CAGR)+22.09%
    Return vs SPY (1Y)+25.35%
    Max Drawdown (1Y)-26.84%
    Max Drawdown (3Y)-33.92%
    Sharpe Ratio (1Y)0.77
    Correlation with SPY (1Y)0.21
    50-Day Average$114.04
    200-Day Average$85.66
    52-Week Range$61.23 to $134.00
    RSI (14 Days)23.4
    Average Volume (20 Days)2.36M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.88x current liabilities.

    Current Ratio3.88x
    Quick Ratio3.60x
    Debt / EBITDA3.97x
    Debt / FCF3.67x
    Interest Coverage24.40x

    Returns and Efficiency

    Return on invested capital is 15.84% over the last 12 months, against a 5-year average of 18.00%.

    Return on Assets (ROA)13.98%
    Return on Invested Capital (ROIC)15.84%
    Return on Capital Employed (ROCE)22.79%
    ROE (5Y Average)286.15%
    ROA (5Y Average)19.55%
    ROIC (5Y Average)18.00%
    Asset Turnover0.63x
    Inventory Turnover2.37x
    Receivables Turnover3.67x
    Cash Conversion Cycle221 days

    Taxes

    Income tax took 25.89% of pretax income over the last 12 months.

    Income Tax (TTM)$169.59M
    Effective Tax Rate25.89%

    Scores

    HALO has an Altman Z-Score of 3.47, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score3.47
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $1.80B over the last 12 months.

    Revenue$1.80B
    Revenue Growth (YoY)+45.03%
    Gross Profit$1.48B
    Operating Income$674.25M
    Pretax Income$655.01M
    Net Income$485.42M
    EBITDA$818.97M
    EBIT$683.00M
    Reported EPS (TTM)$5.42

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$1.03B
    Total Debt$3.25B
    Net Debt$2.22B
    Net Debt Per Share$19.51
    Working Capital$1.37B
    Shareholder Equity-$55.24M
    Tangible Book Value-$1.53B
    Total Assets$3.47B
    Total Liabilities$3.53B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $12.39M of capital spending, operating cash flow left $885.88M of free cash flow.

    Operating Cash Flow$898.27M
    Capital Expenditures$12.39M
    Free Cash Flow$885.88M
    FCF Per Share$7.81
    Depreciation and Amortization$135.97M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 37.41%, against a 5-year average of 46.27%.

    Gross Margin82.27%
    Operating Margin37.41%
    Pretax Margin36.34%
    Net Margin26.93%
    EBITDA Margin45.44%
    EBIT Margin37.89%
    FCF Margin49.15%
    Gross Margin (5Y Average)81.05%
    Operating Margin (5Y Average)46.27%
    Net Margin (5Y Average)44.37%

    Growth

    Revenue grew 28.38% a year over 3 years, and EPS 22.99% a year.

    Revenue Growth (3Y CAGR)+28.38%
    Revenue Growth (5Y CAGR)+39.16%
    EPS Growth (3Y CAGR)+22.99%
    EPS Growth (5Y CAGR)+35.63%
    FCF Growth (3Y CAGR)+39.92%
    FCF Growth (5Y CAGR)+64.85%
    Operating Income Growth (3Y CAGR)+20.58%
    Book Value Per Share Growth (2Y CAGR)-19.46%

    Revenue and profit by year

    Dividends and Yields

    HALO does not pay a dividend. Its free cash flow yield is 8.11%.

    Earnings Yield5.65%
    FCF Yield8.11%
    Buyback Yield0.37%
    Shareholder Yield0.37%

    Peer Position

    Against 7 similar companies, HALO has the lowest P/E.

    P/E Ratio17.7x vs 39.5x median
    P/S Ratio6.1x vs 13.1x median
    ROIC15.84% vs 1.77% median
    Revenue Growth (Trailing 4 Quarters, YoY)+45.03% vs +25.96% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 24.96% and EPS growth at 60.15% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+24.96%
    EPS Growth Forecast (2Y CAGR)+60.15%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HALO

    What is HALO's market cap?

    Halozyme Therapeutics has a market cap of $11.00B. Its enterprise value, which adds debt and subtracts cash, is $13.22B.

    What is HALO's P/E ratio?

    Halozyme Therapeutics has a trailing P/E ratio of 17.7x and a forward P/E of 10.6x.

    How many shares of HALO are outstanding?

    Halozyme Therapeutics has 113.80M shares outstanding. The count is down 2.92% from a year earlier.

    Does HALO pay a dividend?

    No. Halozyme Therapeutics does not pay a dividend.

    How much debt does HALO have?

    Halozyme Therapeutics has $3.25B of total debt and $1.03B of cash and equivalents, a net debt position of $2.22B.